PDCD1 and cancer: Therefore, the current cancer immunotherapy targeting a single target, such as PD-1/PD-L1 inhibitor, Cytotoxic T-lymphocyte Antigen-4 (CTLA-4) inhibitor, and Chimeric antigen receptor (CAR) T-cell therapy (CAR-T), has very limited therapeutic effect on most cancers (58, 59).